Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist
Cephalalgia · 2024
DOI: 10.1177/03331024231226186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, 2024. Verfasst von Eric Moore und 11 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, NJ, USA. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Receptors, Calcitonin Gene-Related Peptide, Piperidines, Pyridines. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
The trigeminal sensory neuropeptide calcitonin gene–related peptide (CGRP) is identified as an essential element in migraine pathogenesis.
Methods
In vitro and in vivo studies evaluated pharmacologic properties of the CGRP receptor antagonist atogepant. Radioligand binding using 125 I-CGRP and cyclic adenosine monophosphate (cAMP) accumulation assays were conducted in human embryonic kidney 293 cells to assess affinity, functional potency and selectivity. Atogepant in vivo potency was assessed in the rat nitroglycerine model of facial allodynia and primate capsaicin-induced dermal vasodilation (CIDV) pharmacodynamic model. Cerebrospinal fluid/brain penetration and behavioral effects of chronic dosing and upon withdrawal were evaluated in rats.
Results
Atogepant exhibited high human CGRP receptor-binding affinity and potently inhibited human α-CGRP-stimulated cAMP responses. Atogepant exhibited significant affinity for the amylin1 receptor but lacked appreciable affinities for adrenomedullin, calcitonin and other known neurotransmitter receptor targets. Atogepant dose-dependently inhibited facial allodynia in the rat nitroglycerine model and produced significant CIDV inhibition in primates. Brain penetration and behavioral/physical signs during chronic dosing and abrupt withdrawal were minimal in rats.
Conclusions
Atogepant is a competitive antagonist with high affinity, potency and selectivity for the human CGRP receptor. Atogepant demonstrated a potent, concentration-dependent exposure/efficacy relationship between atogepant plasma concentrations and inhibition of CGRP-dependent effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, NJ, USA.
- AbbVie, North Chicago, IL, USA.
- AbbVie, Madison, NJ, USA.
Förderung
- AbbVie
Zitieren
APA
Moore, E., Bell, I. M., Fraley, M. E., Burgey, C. S., White, R. B., Li, C. C., Regan, C. P., Danziger, A., McGaraughty, S. P., Naseri Kouzehgarani, G., Salvatore, C., & Banerjee, P. (2024). Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist. Cephalalgia. https://doi.org/10.1177/03331024231226186
Vancouver
Moore E, Bell IM, Fraley ME, Burgey CS, White RB, Li CC, et al. Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist. Cephalalgia. 2024. doi:10.1177/03331024231226186
BibTeX
@article{Moore2024,
author = {Moore, Eric and Bell, Ian M and Fraley, Mark E and Burgey, Christopher S and White, Rebecca B and Li, Chi-Chung and Regan, Christopher P and Danziger, Andrew and McGaraughty, Steve P and Naseri Kouzehgarani, Ghazal and Salvatore, Christopher and Banerjee, Pradeep},
title = {Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024231226186}
}
EUVIMED